Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma

Engineering Stimuli‐Activatable Boolean Logic Prodrug Nanoparticles for Combination Cancer Immunotherapy

(2020) Bo Hou et al.   ADVANCED MATERIALS

CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice

(2020) Yinan Zhong et al.   JOURNAL OF CONTROLLED RELEASE

Reverse immune suppressive microenvironment in tumor draining lymph nodes to enhance anti-PD1 immunotherapy via nanovaccine complexed microneedle

(2020) Zhongzheng Zhou et al.   Nano Research

A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy

(2020) Di-Wei Zheng et al.   Nature Communications

Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles

(2020) Bi Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities

(2020) Anna Lucia Tornesello et al.   MOLECULES

GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma

(2020) Cheng Zhou et al.   Acta Biomaterialia

An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles

(2020) Jiayan Wu et al.   Science Advances

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC

(2020) Yu Gu et al.   Advanced Science

Immune-adjuvant loaded Bi2Se3 nanocage for photothermal-improved PD-L1 checkpoint blockade immune-tumor metastasis therapy

(2019) Yilin Song et al.   Nano Research

Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo

(2019) Yaohua Wei et al.   Acta Biomaterialia

Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma

(2019) Jing Nie et al.   JOURNAL OF CLINICAL ONCOLOGY

CD44‐Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma

(2019) Wenxing Gu et al.   ADVANCED MATERIALS

CAR-NK for tumor immunotherapy: Clinical transformation and future prospects

(2019) Wenxiu Wang et al.   CANCER LETTERS

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

(2018) Dmitriy Zamarin et al.   JOURNAL OF CLINICAL INVESTIGATION

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

(2018) Julia A Beaver et al.   LANCET ONCOLOGY

Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment

(2018) Michel L. Leite et al.   PHARMACOLOGY & THERAPEUTICS

A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.

(2018) James F. Spicer et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model

(2018) Mayu Tomita et al.   EJNMMI Research

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

(2018) Leisha A. Emens et al.   JAMA Oncology

Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma

(2018) Yu Jiang et al.   ACS Nano

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

(2018) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

(2018) Marcin Kowanetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment

(2017) Baldur Sveinbjørnsson et al.   Future Medicinal Chemistry

Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines

(2017) Yerly Vargas Casanova et al.   MOLECULES

cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma

(2017) Ping Zhong et al.   NANOTECHNOLOGY

Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody

(2016) Chao Wang et al.   ADVANCED MATERIALS

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

(2016) T Yamazaki et al.   CELL DEATH AND DIFFERENTIATION

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Antimicrobial peptides

(2016) Ling-juan Zhang et al.   CURRENT BIOLOGY

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

(2016) Bengt Erik Haug et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

(2015) J. Spicer et al.   EUROPEAN JOURNAL OF CANCER

CpG-A stimulates Hsp72 secretion from plasmacytoid dendritic cells, facilitating cross-presentation

(2015) Tsutomu Tanaka et al.   IMMUNOLOGY LETTERS

A Tetrameric Peptide Derived from Bovine Lactoferricin Exhibits Specific Cytotoxic Effects against Oral Squamous-Cell Carcinoma Cell Lines

(2015) Víctor A. Solarte et al.   Biomed Research International

Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity

(2015) Yongkui Li et al.   OncoImmunology

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

(2014) Ketil André Camilio et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

(2014) S. Chen et al.   Cancer Immunology Research

Cross-presentation by human dendritic cell subsets

(2013) Elodie Segura et al.   IMMUNOLOGY LETTERS

Immune modulation by multifaceted cationic host defense (antimicrobial) peptides

(2013) Ashley L Hilchie et al.   Nature Chemical Biology

Antitumor Activity Mediated by CpG

(2011) Yanyan Lou et al.   JOURNAL OF IMMUNOTHERAPY

CpG Promotes Cross-Presentation of Dead Cell-Associated Antigens by Pre-CD8 + Dendritic Cells

(2010) C. de Brito et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

(2009) Jeffrey S. Weber et al.   CANCER